GlassScriptPhysician profile
James F Sullivan
NPI 1346236379
$100,101.65
in general payments reported to CMS, 2019-2025
23 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $8,569 · 2021: $9,884 · 2022: $14K · 2023: $13K · 2024: $12K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $6,668 · Food and Beverage: $5,557 · Education: $21.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,620.00 |
| Travel and Lodging | $6,667.58 |
| Food and Beverage | $5,557.41 |
| Education | $21.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $67,342.38 | 2019-2025 | Biktarvy, Sunlenca |
| Janssen Products, LP | $24,993.62 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $2,741.57 | 2019-2025 | Dovato, Apretude, Rukobia |
| Merck Sharp & Dohme LLC | $1,076.13 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $951.75 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $731.19 | 2019-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Abbvie INC. | $456.17 | 2019-2025 | Avycaz, Mavyret |
| Napo Pharmaceuticals INC | $421.93 | 2019-2025 | Mytesi |
| Shionogi INC | $280.14 | 2019-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $259.72 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $228.46 | 2019-2025 | Trogarzo, Egrifta |
| Tetraphase Pharmaceuticals, INC. | $126.62 | 2019 | |
| Allergan, INC. | $78.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.86 | 2022-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $65.52 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $53.24 | 2019-2022 | |
| Astellas Pharma US INC | $52.91 | 2019-2024 | Cresemba |
| Nabriva Therapeutics, Plc | $45.62 | 2020 | |
| Boston Scientific Corporation | $34.11 | 2025 | Farapulse |
| Abbott Laboratories | $27.22 | 2023 | Xience Sierra |
| Exact Sciences Corporation | $25.94 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.37 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.